Biogen Inc 's Cash & cash equivalent grew by 11.5 % in the Q1 2026 sequentially, while Current Liabilities decreased, this led to improvement in Biogen Inc 's Quick Ratio to 0.3, Quick Ratio remained below Biogen Inc average.

Within Biotechnology & Pharmaceuticals industry 125 other companies have achieved higher Quick Ratio than Biogen Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 753 to 2734.

Explain Quick Ratio?
How much Cash & cash equivalents BIIB�s has?
What are BIIB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BIIB Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1
Y / Y Current Liabilities Change	-43.39 %	-39.42 %	-39.35 %	2.43 %	64.37 %
Y / Y Cash & cash equivalent Change	-	-	-	-	-
Quick Ratio MRQ	0.3	0.24	0.03	-	-
BIIB's Total Ranking	# 2734	# 753	# 783	# 0	# 0
Seq. Current Liabilities Change	-10.46 %	1.81 %	3.34 %	-39.9 %	-4.19 %
Seq. Cash & cash equivalent Change	11.5 %	727.05 %	-	-	-

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 126
Healthcare Sector	# 760
Overall Market	# 2734

Quick Ratio Statistics
High	Average	Low
3.22	1.1	0.03
(Dec. 31, 2005)		(Sep 30 2025)

Financial Statements
Biogen Inc 's Current Liabilities	$ 2,999 Millions	Visit BIIB's Balance sheet
Biogen Inc 's Cash & cash equivalent	$ 900 Millions	Visit BIIB's Balance sheet
Source of BIIB's Sales		Visit BIIB's Sales by Geography

Cumulative Biogen Inc 's Quick Ratio

BIIB's Quick Ratio for the trailling 12 Months

BIIB Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-33.77 %	-12.52 %	12.04 %	29.23 %	28.06 %
Y / Y Cash & cash equivalent TTM Growth	-	-	-	-	-
Quick Ratio TTM	0.14	0.06	0.01	-	-
Total Ranking TTM	# 3233	# 953	# 684
Seq. Current Liabilities TTM Growth	-15.2 %	-12.6 %	-10.99 %	0.39 %	12 %
Seq. Cash & cash equivalent TTM Growth	99.47 %	827.05 %	-	-	-

Quick ratio ranking by company, industry and sector >> Back to BIIB Financial Strength Comparisons >> Go to Compare BIIB Quick Ratio to its Competitors

On the trailing twelve months basis BIIB Cash & cash equivalent increased by 11.5 % in Q1 2026 year on year, while Current Liabilities fell to $2,999 millions, this led to increase in in Biogen Inc 's Quick Ratio to 0.14, Quick Ratio remained below BIIB average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 125 other companies have achieved higher Quick Ratio than Biogen Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 953 to 3233.

Explain Quick Ratio?
How much Cash & cash equivalents BIIB�s has?
What are BIIB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 126
Healthcare Sector	# 760
Within the Market	# 3233

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.22	1.1	0.03
(Dec. 31, 2005)		(Sep 30 2025)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Dbv Technologies S a	0.75	$ 42.600 Millions	$ 56.796 Millions
Xtant Medical Holdings Inc	0.65	$ 12.137 Millions	$ 18.773 Millions
Senti Biosciences Holdings Inc	0.63	$ 8.935 Millions	$ 14.268 Millions
Silexion Therapeutics Corp	0.60	$ 2.440 Millions	$ 4.060 Millions
Atlantic Coastal Acquisition Corp Ii	0.60	$ 5.453 Millions	$ 9.117 Millions
Zeo Scientifix Inc	0.59	$ 1.846 Millions	$ 3.111 Millions
Sangamo Therapeutics Inc	0.52	$ 27.586 Millions	$ 53.134 Millions
Amgen Inc	0.48	$ 12,038.000 Millions	$ 24,955.000 Millions
Biomx Inc	0.48	$ 1.168 Millions	$ 2.447 Millions
Surrozen Inc	0.44	$ 106.910 Millions	$ 243.155 Millions
Meiragtx Holdings Plc	0.41	$ 71.541 Millions	$ 176.127 Millions
Biocardia Inc	0.34	$ 0.951 Millions	$ 2.778 Millions
Biogen Inc	0.30	$ 900.000 Millions	$ 2,998.900 Millions
Pluri Inc	0.29	$ 9.322 Millions	$ 32.006 Millions
Viskase Holdings inc	0.25	$ 28.619 Millions	$ 112.789 Millions
Champions Oncology Inc	0.24	$ 4.872 Millions	$ 19.922 Millions
Outlook Therapeutics Inc	0.20	$ 7.748 Millions	$ 38.884 Millions
Agenus Inc	0.14	$ 34.996 Millions	$ 249.237 Millions
Vaxart Inc	0.13	$ 10.276 Millions	$ 76.842 Millions
ADAPTIN BIO, INC.	0.11	$ 0.301 Millions	$ 2.792 Millions
Tevogen Bio Holdings Inc	0.10	$ 0.692 Millions	$ 6.941 Millions
Aptose Biosciences Inc	0.09	$ 1.020 Millions	$ 11.159 Millions
Bioatla Inc	0.08	$ 1.961 Millions	$ 23.633 Millions

Date modified: 2026-09-26T07:00:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.